Valye reports for unlimited access

AudioEye, Inc. is a publicly traded company on the Nasdaq Capital Market under the ticker AEYE. The company is incorporated in Delaware and headquartered in Tucson, Arizona. It operates with a Board of Directors comprising both executive and independent members, including CEO David Moradi who also serves as Chairman. The company reported $40.3 million in revenue and a net loss of $3.08 million for the fiscal year ended December 31, 2025. Its liquidity position as of year-end 2025 shows current liabilities exceeding current assets, with a current ratio of 0.88 and a cash ratio of 0.37. Executive compensation includes base salary, annual bonuses, and long-term equity incentives linked to performance metrics such as monthly recurring revenue and stock price. The company is classified as a smaller reporting company and is not an emerging growth company. Recent news coverage includes multiple articles on the company’s stock performance and earnings.

Splash Beverage Group, Inc. operates in the beverage sector, with a focus on branded alcoholic and non-alcoholic beverages. The company is incorporated in Nevada and headquartered in Fort Lauderdale, Florida. It is listed on the NYSE American exchange under the ticker SBEV. The company’s product portfolio includes Pulpoloco Sangria, which has recently expanded distribution through Total Wine & More. The company’s governance structure includes a five-member board with independent directors and committees overseeing audit, compensation, and governance. Financially, the company reported modest revenues but significant net losses for the fiscal year ended December 31, 2025, alongside a challenging liquidity position. The company has several loan and security agreements with outstanding obligations and related party advances. Recent management changes include the appointment of an interim CFO and director resignations. The company has received multiple buy recommendations from analysts in 2023.

Genco Shipping & Trading Limited is a global drybulk shipping company operating a fleet of 42 vessels, including Capesize, Ultramax, and Supramax classes. The company transports a variety of drybulk commodities such as iron ore, coal, grain, and steel products across international waters. Genco manages its fleet through a joint venture ship management company, consolidating its operations. The company reports financials segmented by major and minor bulk vessels, reflecting its operational focus. Genco maintains liquidity with cash and equivalents of $55.5 million and a current ratio of 2.39 as of the end of 2025. The company has experienced net losses in recent periods but continues to operate with significant equity and manageable liabilities. Corporate governance includes an experienced leadership team and recent initiatives to enhance employee retention. Genco has actively responded to takeover bids and maintains a dividend policy. The company’s financial and operational disclosures are comprehensive, providing transparency into its business model and market activities.

Catalyst Pharmaceuticals, Inc. is a Delaware-based pharmaceutical company specializing in treatments for orphan and rare diseases. The company markets products such as FIRDAPSE® and AGAMREE®, which contribute significantly to its revenues. Catalyst operates with a focus on clinical development, commercialization, and strategic acquisitions to expand its portfolio. The company maintains a strong liquidity position with substantial cash reserves and low current liabilities. Its leadership team includes experienced pharmaceutical executives, with a board comprising industry veterans. Catalyst sources active pharmaceutical ingredients and finished products from both domestic and international suppliers, including partnerships with Santhera and Eisai. The company has implemented a share repurchase program to manage capital and enhance shareholder value. Catalyst faces industry-specific risks including potential tariffs on imports and regulatory pricing policies that could impact costs and market access.

Edible Garden AG Inc operates in the sustainable agriculture and food products sector, offering branded product lines such as Pickle Party™, Pulp®, and Kick. Sports Nutrition. The company has expanded its national distribution footprint through partnerships with retailers like Safeway and PriceSmart Warehouse Clubs, and has launched products on Amazon. It has also opened a new facility in Iowa to support its strategic growth in sustainable agriculture. The company has pursued acquisitions, including NaturalShrimp assets, to strengthen its market position. Leadership includes experienced executives and a board with expertise in capital markets and food retail. The company is publicly traded on Nasdaq under ticker EDBL and maintains governance policies including a Code of Ethics and insider trading rules [N1][N3][N4][N5][N7][N8][S1].

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company incorporated in Nevada in 2017, focused on developing therapies for brain and central nervous system cancers. Its lead drug candidates are TPI 287, a third-generation taxane derivative designed to penetrate the blood-brain barrier and overcome drug resistance, and Berubicin, an anthracycline chemotherapy agent also capable of crossing the blood-brain barrier. Both drugs have received Orphan Drug Designation from the FDA, providing potential market exclusivity. TPI 287 has been studied in early-phase clinical trials across multiple cancer indications involving the CNS. Berubicin has undergone a Phase II trial comparing it to Lomustine in Glioblastoma Multiforme patients who failed first-line therapy; the trial showed comparable clinical outcomes but did not meet the primary endpoint of statistically significant overall survival improvement. The company holds exclusive licenses for its drug candidates and outsources manufacturing and sales functions. Financially, CNS Pharmaceuticals reported a net loss of approximately $15.85 million for fiscal year 2025, with cash and equivalents of $7.2 million and a current ratio near 2. The company is subject to Nasdaq listing requirements and has experienced prior compliance challenges but is currently compliant. CNS Pharmaceuticals continues to evaluate development paths for its drug candidates and plans further clinical trials subject to financing and regulatory approvals.

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for cancer, with a focus on immuno-oncology. Its lead candidate, IFx-2.0, targets advanced cutaneous melanoma and metastatic Merkel cell carcinoma. The company has expanded its pipeline through the acquisition of Kineta, Inc. in 2025. TuHURA's development programs are supported by regulatory designations such as FDA Orphan Drug status, and it is actively conducting clinical trials including a Phase 3 study. The company finances its operations through equity offerings and a revolving credit facility, reflecting its status as a development-stage entity with no current product revenue.

Greenlane Holdings, Inc. is a publicly traded company incorporated in Delaware and headquartered in Boca Raton, Florida. It operates through Greenlane Holdings, LLC and its subsidiaries. The company has recently shifted focus to include a digital asset treasury strategy alongside its legacy business operations. This strategy involves acquisition, lending, and trading of digital assets, including BERA tokens, under agreements with third parties. The company maintains a Board of Directors with five independent members and four standing committees, including a Digital Assets Committee to oversee digital asset activities and risk management. Key executives include CEO Jason Hitchcock, CFO Vanessa Guzmán-Clark, and CIO Benjamin Isenberg. Financially, as of December 31, 2025, Greenlane held $32.5 million in cash and equivalents, with a current ratio of 5.01, indicating strong liquidity. The company reported a net loss of $85.6 million for fiscal 2025 and modest revenue of $737,000 for Q3 2025. Greenlane faced a Nasdaq delisting notice in March 2026 due to minimum bid price non-compliance but regained compliance by April 21, 2026, maintaining its listing on the Nasdaq Capital Market. The company has related-party transactions with entities owned by executives, conducted on arm's-length terms with oversight. Executive compensation includes base salary, discretionary bonuses, and equity awards with severance provisions. The company continues to evolve its governance and operational structure to support its strategic initiatives [S1][N1][N2].

LENSAR, Inc. develops and markets ophthalmic medical devices, including the ALLY Robotic Cataract Laser System, targeting the cataract surgery market. The company is headquartered in Orlando, Florida, and is publicly traded on the Nasdaq under the ticker LNSR. Its business model centers on selling advanced laser systems and related technologies to eye care providers. Recent financial disclosures show revenue growth driven by increased system placements. The company has engaged in strategic merger discussions with Alcon Research, which were terminated in early 2026. LENSAR also provides equity-based incentives to attract and retain talent. The company maintains liquidity through cash, short-term investments, and a revolving credit facility secured by brokerage assets.

Interpace Biosciences, Inc. operates as a publicly reporting company with a structured board and executive leadership team. The company has disclosed financial results including revenue, net income, and earnings per share for recent fiscal years. It maintains equity incentive plans for executives and directors and has established compensation policies. The company has a current ratio near 2, indicating liquidity above current liabilities. Recent news coverage includes earnings performance and investor activity.

Synlogic, Inc. is a biotechnology company incorporated in Delaware, with its principal executive offices in Winchester, Massachusetts. The company operates with a small team focused on strategic transactions and governance oversight. Synlogic's Board of Directors comprises experienced professionals with backgrounds in life sciences, finance, and corporate governance. The company is currently traded on the OTC Marketplace following delisting from Nasdaq. Financial disclosures indicate no revenue generation in 2025 and a net loss, but with a strong liquidity position supported by cash and current assets exceeding current liabilities. Synlogic has engaged in government subcontracting and has received analyst coverage with buy recommendations.

RE/MAX Holdings, Inc. is a real estate franchising company operating through reportable segments: Real Estate, Mortgage, and Marketing Funds. The company generates revenue primarily from continuing franchise fees paid by franchisees based on agent counts or office numbers, annual dues charged directly to agents, broker fees on real estate commissions, marketing funds fees used for brand marketing and technology support, and franchise sales including initial franchise sales, renewals, and master franchise fees. Additional revenue sources include data services, technology subscriptions, events, mortgage loan processing, and advertising. The company maintains deferred revenue primarily from franchise sales and annual dues. As of the end of 2025, RE/MAX Holdings had a current ratio of 1.69 and a cash ratio of 0.84, indicating liquidity. The company’s governance includes a board of eight directors with staggered terms, including co-founder David L. Liniger as Chair and Erik Carlson as CEO since late 2023. Recent quarterly financials show revenues exceeding $220 million for the first nine months of 2025, with operating expenses including selling, administrative, marketing, depreciation, and settlement charges. Cash flow from operations was positive, supporting ongoing investments in property, equipment, and software. The company also provides marketing and technology services to its franchisees, including website and app maintenance and consumer-facing platforms.

RingCentral, Inc. operates in the cloud-based business communications sector, providing unified communications as a service (UCaaS), contact center as a service (CCaaS), and software-as-a-service (SaaS) solutions. Its core offerings include voice, video, messaging, and contact center subscriptions delivered primarily through its RingEX platform. The company integrates AI features such as AI Receptionist and AI Virtual Assistant to enhance its product suite. RingCentral distributes its services globally, with significant operations in North America, Europe, and Asia-Pacific regions. It relies heavily on a network of channel partners, global service providers, and strategic partnerships to market and sell its subscriptions. The company also depends on third-party vendors for critical service components and operates data centers leased from providers like Equinix, AWS, and Google Cloud. RingCentral's governance includes a board of directors with expertise in technology, finance, and venture capital, led by co-founder and CEO Vladimir Shmunis. The company has recently initiated a quarterly cash dividend program and maintains a capital structure with outstanding term loans and revolving credit facilities subject to restrictive covenants.

International Money Express, Inc. (Intermex) operates as a leading omnichannel remittance service provider, offering money transfer services primarily targeting immigrant communities. The company combines a retail agent network with digital platforms to facilitate cross-border remittances. Intermex's business model leverages both physical retail locations and digital infrastructure to serve customers. The company is headquartered in Miami, Florida, and is incorporated in Delaware. Intermex's board of directors consists of eight members divided into three classes to ensure continuity and stability. The executive leadership team includes experienced professionals with backgrounds in financial services and payment processing. For the fiscal year ended December 31, 2025, Intermex reported revenues of $607.8 million, net income of $32.7 million, and diluted EPS of $1.08. The company maintains a strong liquidity position with $168.7 million in cash and cash equivalents and a current ratio of 2.51. Intermex is currently subject to a pending merger agreement with The Western Union Company, under which Western Union will acquire Intermex for $16.00 per share in cash, representing approximately a 50% premium to the recent trading price. The merger is subject to customary closing conditions including stockholder approval and regulatory clearances. The company faces risks related to the merger process, including potential disruptions to business relationships, employee retention, and operational restrictions.

Navitas Semiconductor Corporation develops and markets gallium nitride (GaN) power integrated circuits and semiconductor solutions. The company is publicly traded on Nasdaq under the ticker NVTS and is headquartered in Torrance, California. Navitas is transitioning its business focus from mobile and consumer electronics to high-power markets including AI data centers, performance computing, energy and grid infrastructure, and industrial electrification. This strategic shift requires new product development, customer acquisition, and supply chain adjustments. Navitas relies on TSMC as its sole GaN wafer supplier but is qualifying Powerchip Semiconductor as an alternative due to TSMC's planned discontinuation of GaN production by mid-2027. The company reported a net loss for fiscal year 2025 and maintains strong liquidity ratios. Its board consists of ten members with a majority independent directors. Navitas has announced collaborations with industry participants such as Nvidia to advance power delivery technologies for AI data centers. The company faces risks related to market acceptance, competition, supply chain transitions, and cyclical industry conditions [S1][S2].

Achieve Life Sciences, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a product candidate intended to aid smoking cessation. The company has not yet generated revenue from product sales and has incurred significant net losses. Its financial position as of December 31, 2025, includes $20.9 million in cash and $15.5 million in short-term investments, with a current ratio of 4.39, indicating strong liquidity. The company has raised capital through public offerings and convertible debt agreements to fund its clinical development and commercialization efforts. The company submitted a New Drug Application for cytisinicline to the FDA in June 2025 and has formed partnerships to support its U.S. launch strategy. Leadership includes experienced biopharma executives and medical professionals. The company has disclosed material uncertainty regarding its ability to continue as a going concern without additional financing.

Ready Capital Corporation operates as a mortgage real estate investment trust (REIT) externally managed by Waterfall Asset Management. The company invests primarily in commercial real estate loans and mortgage-backed securities, focusing on generating distributable earnings for shareholders. Its management team includes experienced professionals with backgrounds in securitization, real estate finance, and investment banking. The company maintains a diverse board of directors with expertise in real estate and finance. Ready Capital issues common stock, preferred stock, and senior notes, and regularly files detailed financial reports with the SEC. The company has disclosed executive compensation aligned with performance metrics such as distributable return on equity. Recent financial disclosures indicate challenges with quarterly losses and revenue performance, consistent with the broader mortgage REIT sector environment.

Catheter Precision, Inc. operates in the medical device sector, specializing in cardiac electrophysiology technologies. Its two main products are the VIVO System, which provides 3D cardiac mapping to assist in localizing ventricular arrhythmias prior to ablation procedures, and LockeT, a suture retention device designed to improve wound closure outcomes. The VIVO System has FDA clearance and CE Mark approval, with usage in over 1,000 procedures in the U.S. and EU. LockeT is FDA registered and has received CE Mark approval, enabling sales expansion in Europe and the UK. The company has formed subsidiaries Cardionomix and KardioNav to develop and commercialize advanced cardiac treatment technologies, including the CPNS System and ventricular tachycardia ablation innovations. Recent acquisitions include PeriKard, LLC and Cardionomic assets, recognized as in-process research and development. The company generates revenue primarily from product sales, with a portion from international markets. It has experienced net losses and liquidity constraints, with ongoing efforts to secure financing and expand its product portfolio and market reach.

Alchemy Investments Acquisition Corp 1 is a special purpose acquisition company incorporated in the Cayman Islands and listed on Nasdaq under ticker ALCY. The company completed its IPO in May 2023, raising net proceeds placed in a trust account invested in U.S. government treasury obligations. The company is pursuing a business combination with Cartiga, LLC, a litigation finance asset management platform. The transaction involves a domestication and merger process resulting in a new publicly traded entity named Cartiga Holdings, Inc., operating under an Up-C structure. The company has executed multiple ancillary agreements to support the business combination, including support, lock-up, and registration rights agreements. The closing of the business combination is subject to customary conditions such as shareholder approvals, Nasdaq listing approval, and minimum cash requirements. The company reported a net loss of $1.1 million for the year ended December 31, 2025, with limited liquidity outside the trust account. The company’s shares are actively traded, and recent news highlights progress toward completing the business combination.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting immune-mediated diseases. Founded in 2015 and headquartered in South San Francisco, the company operates primarily in one segment. Its lead product candidate, zetomipzomib, is being developed for autoimmune hepatitis and other indications. Kezar has licensed rights to zetomipzomib in Greater China and select Asian territories to Everest Medicines Limited, receiving upfront payments and potential milestone payments. The company has conducted multiple clinical trials, including a Phase 2a trial for autoimmune hepatitis, which had a partial clinical hold lifted by the FDA in mid-2025. Kezar has experienced operating losses since inception and has funded operations through equity and collaborations. In late 2025, the company initiated a strategic alternatives review, including workforce reductions and cost containment. In early 2026, Aurinia Pharma announced a proposed acquisition of Kezar.

Seer, Inc. develops and commercializes the Proteograph Product Suite, a proteomics technology platform comprising automation instruments, consumables, proprietary nanoparticle technology, and software for proteome analysis. The company targets commercial companies, academic institutions, and research organizations. Seer is in the early commercialization phase, with revenues concentrated among a small number of customers. Manufacturing is outsourced to Hamilton Company, with complex quality control processes. The company faces competition from established life sciences firms and emerging proteomics companies. Seer’s products are labeled for research use only and are not intended for clinical diagnostics. The company maintains a strong cash position and is investing in sales, marketing, and product development to drive adoption and growth.

Olaplex Holdings, Inc. operates in the beauty and personal care industry, focusing on haircare products and related technologies. The company is headquartered in New York and is publicly listed on Nasdaq under the ticker OLPX. Olaplex's governance structure includes a staggered Board of Directors with members experienced in retail, finance, and consumer products. Amanda Baldwin has served as CEO since December 2023, bringing extensive beauty industry and investment experience. The company completed the acquisition of Purvala Bioscience, a bioinspired technology firm, in August 2025 to enhance its innovation capabilities. Olaplex reported a net loss for fiscal 2025 but maintains strong liquidity ratios. It is currently subject to a pending acquisition agreement by Henkel valued at approximately $1.4 billion. The company emphasizes risk management, including cybersecurity and market competition, and aligns executive compensation with industry peers.

Cumulus Media Inc operates as a multi-platform audio-first media company with a broad portfolio of local radio stations and digital audio content. The company generates revenue primarily from advertising across its spot, network, and digital platforms. It has experienced revenue declines in recent quarters due to macroeconomic pressures affecting advertising demand. The company filed for Chapter 11 bankruptcy in March 2026 to implement a prepackaged restructuring plan supported by major lenders and noteholders. The plan includes cancellation of existing equity, issuance of new common stock and warrants to creditors, and continuation of operations under bankruptcy protection. The company’s stock was delisted from Nasdaq in May 2025 and now trades on the OTCQB market. Liquidity as of March 31, 2026, includes $57.6 million in cash and a strong current ratio, supporting ongoing operations during restructuring. The company continues to invest in programming initiatives such as new podcasts to enhance its content offerings.

Meridian Holdings Inc., formerly Golden Matrix Group, is a Nevada-based company listed on NASDAQ under the ticker MRDN. The company acquired MeridianBet Group in 2024, which operates gaming and betting services in over 30 jurisdictions across Europe, Africa, and Latin America. The company’s leadership team includes experienced executives with backgrounds in finance, gaming, and operations. Meridian Holdings reported $50.1 million in revenue and $2.17 million in net income for the quarter ended March 31, 2026. The company’s liquidity position shows a current ratio below 1, indicating current liabilities exceed current assets. The company is actively pursuing regulatory licenses in Brazil and Ontario and has resumed a stock repurchase program. Insider buying and selling activity has been notable in recent months.

ASP Isotopes Inc. is a publicly traded company on Nasdaq (ticker: ASPI) headquartered in Dallas, Texas. The company focuses on the production and development of helium resources and advanced nuclear fuel technologies. It completed the acquisition of Renergen Limited, advancing its helium extraction operations. ASP Isotopes also pursues strategic collaborations in energy research, including partnerships for lithium laser research facilities. The company is led by founder and CEO Paul E. Mann, supported by a board with expertise in nuclear energy, fusion technology, and investment management. Financially, ASP Isotopes reported revenues of $23.8 million and a net loss of $159.8 million for the fiscal year ending December 31, 2025, with a strong liquidity profile evidenced by substantial cash reserves and a high current ratio.

MicroVision, Inc. operates in the advanced technology sector, specializing in lidar sensor technology and autonomous perception systems primarily for mobility and transportation industries. The company has transitioned from research and development to product commercialization, focusing on intelligent mobility solutions. Leadership includes CEO Glen W. DeVos, who brings extensive experience in automotive and technology innovation. The company completed a strategic acquisition of Luminar Technologies' lidar sensor assets in early 2026, enhancing its product portfolio. Financially, MicroVision reported a net loss in 2025 and maintains liquidity through cash reserves and convertible notes. The company is publicly traded on NASDAQ under the ticker MVIS and has received recent analyst buy recommendations.

Safe Pro Group Inc. operates in the defense technology sector, specializing in AI applications for landmine detection and manufacturing bullet and blast resistant personal protection equipment primarily for military and government customers. The company has strategic partnerships, including with Ukraine's Center of Excellence, to advance AI-driven defense solutions. Leadership includes experienced executives with military and technology backgrounds. The company is publicly traded on NASDAQ and has engaged in capital raising activities to support its growth and technology development.

OneMedNet Corp operates in the healthcare IT sector, providing platforms and solutions for healthcare data sharing, discovery, and analytics. The company’s offerings support improved healthcare outcomes and AI development by enabling access to real-world and multimodal patient data. Leadership includes experienced healthcare IT executives and medical professionals. The company has engaged in strategic partnerships to expand its data capabilities and has raised capital through private placements and shareholder loans. Financially, OneMedNet reported modest revenues and net losses in 2025, with liquidity ratios indicating current liabilities exceed current assets. The company has taken steps to regain compliance with Nasdaq listing requirements.

Wave Life Sciences Ltd. is a biotechnology company specializing in the development of stereopure RNA-based therapeutics. The company is incorporated in Singapore and trades on the Nasdaq Global Market under the ticker WVE. Its leadership team includes CEO Paul B. Bolno, M.D., MBA, who has been with the company since 2013. The company’s pipeline includes programs such as WVE-007 for obesity and other RNA editing candidates. As of the first quarter of 2026, Wave Life Sciences reported a net loss and maintains a strong liquidity position with over $544 million in cash and equivalents. The company recently undertook a corporate redomiciliation to Delaware. Its executive compensation program aligns management incentives with shareholder interests. The company faces typical biotech risks including clinical trial outcomes, regulatory approvals, and financing needs.

Transcode Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA-based therapeutics targeting cancer. The company’s lead candidate, TTX-MC138, is an RNA cancer therapy that has progressed through Phase 1 clinical trials and entered Phase 2a as part of the Quantum Leap PRE-I-SPY platform. The company completed the acquisition of Polynoma, a biopharmaceutical entity, from CK Life Sciences in 2025, expanding its pipeline and capabilities. Transcode has engaged in multiple financing activities, including stock and warrant offerings and private placements, to fund its clinical development and operations. The company maintains a strong liquidity position with cash and equivalents of approximately $17.8 million as of the end of 2025 and a current ratio above 6, indicating sufficient short-term assets to cover liabilities. Leadership includes CEO Philippe P. Calais, appointed in 2025, bringing decades of biotech experience, and CFO Thomas A. Fitzgerald, who also served as interim CEO. The company regained Nasdaq listing compliance in early 2025 after prior non-compliance. Transcode’s business model focuses on advancing RNA-based oncology therapies through clinical development, strategic acquisitions, and capital raising to support growth and pipeline advancement.

Arcadia Biosciences, Inc. is a Delaware-incorporated company focused on agricultural biotechnology and related products. The company is publicly traded on the NASDAQ Capital Market under the ticker RKDA. It operates with a board of directors and executive officers experienced in finance, agriculture, and corporate governance. The company has engaged in strategic transactions including a proposed all-stock merger with Roosevelt Resources announced in late 2024, which was subsequently terminated in December 2025. Financially, the company has reported recurring net losses and an accumulated deficit, with liquidity supported by cash, short-term investments, and current assets exceeding current liabilities as of December 31, 2025. The company has disclosed material weaknesses in internal controls related to segregation of duties and information system controls, attributed to reduced employee headcount. Recent equity financing activities include inducement agreements with investors to exercise preferred investment options at reduced prices. The company regularly reports quarterly and annual financial results and maintains governance policies including a code of business conduct and ethics.

Surf Air Mobility Inc. operates in the air mobility sector, providing scheduled air services including Essential Air Service routes to small U.S. communities. The company is incorporated in Delaware and headquartered in Hawthorne, California. It maintains multi-year contracts with the U.S. Department of Transportation to support these routes. The company has a board of directors with staggered terms and experienced executives, including CEO Deanna White and CFO Oliver Reeves. Financially, the company reported a significant net loss in 2025 and maintains liquidity through cash, credit facilities, and equity offerings. It has entered into secured promissory notes and reimbursement agreements with affiliated entities to support its capital structure. Recent news highlights include revised loss outlooks and continued operational activity despite federal funding uncertainties.

XWELL, Inc. operates in the wellness industry, providing services through wellness centers, spas, and medical spa markets. The company has pursued growth through strategic acquisitions and partnerships, including collaborations with Priority Pass and the Orlando Magic. XWELL's Xpres Spa brand has received recognition as a popular airport wellness brand. The company has expanded its physical presence with new wellness centers, such as the one opened in Clearwater, Florida. Leadership includes CEO Ezra T. Ernst and CFO Thomas Ian Brown, supported by a board with expertise in finance, branding, and customer experience. Financially, XWELL reported $29.21 million in revenue and a net loss of $16.991 million for 2025, with liquidity challenges reflected in a current ratio below 1. The company has raised capital through convertible preferred stock offerings to support its expansion and operations.

Aqua Metals, Inc. operates in the sustainable lithium battery recycling sector, developing technologies and processes aimed at recovering critical minerals and producing recycled battery materials. The company is headquartered in Reno, Nevada, and is publicly traded on Nasdaq under the ticker AQMS. Its leadership team includes President and CEO Stephen Cotton, CFO Eric West, and Chief Engineering and Operations Officer Benjamin Taecker. The Board of Directors comprises four members, including independent directors with expertise in finance, manufacturing, and automotive sectors. Aqua Metals has implemented governance policies separating the roles of chairman and CEO and has a director resignation policy to maintain board effectiveness. The company has a compensation framework involving short-term and long-term incentive plans with equity awards tied to performance and retention. Financially, as of the fiscal year ending December 31, 2025, Aqua Metals held $10.81 million in cash and equivalents, with a current ratio of 3.03, but reported a net loss of $22.646 million and a basic EPS of -15.15. The company has reported limited recent revenue data, with the last known revenue figure from 2017. Recent operational developments include milestones in lithium battery recycling pilot projects, production of 100% recycled nickel cathode active material, and a lithium purity record. The company also executed a 1-for-10 reverse stock split in mid-2025 and has experienced leadership transitions, including a new CFO appointment. Aqua Metals actively engages with industry events and investor communications through earnings calls and public disclosures.

Enhabit, Inc. operates in the healthcare sector, focusing on home health and hospice care services. The company became an independent public entity in July 2022 following a separation from Encompass Health Corporation. It is listed on the New York Stock Exchange under the ticker EHAB. The company’s leadership team has extensive experience in healthcare operations, finance, legal, and human resources. Enhabit maintains governance structures with independent board committees overseeing audit, compensation, and compliance. Financially, as of December 31, 2025, the company held $43.6 million in cash and equivalents, with current assets exceeding current liabilities, resulting in a current ratio of 1.63. The company reported a net loss of $4.6 million for the fiscal year 2025. Enhabit has credit facilities totaling $475 million, including a term loan and revolving credit facility, secured by company assets and subject to customary covenants. Recent public disclosures include multiple earnings call transcripts and news coverage of an acquisition agreement with Kinderhook.

Trump Media & Technology Group Corp. is a publicly traded company listed on Nasdaq and NYSE Texas under the ticker DJT. The company operates primarily in the technology and media sectors, focusing on social media platforms, streaming services, and digital asset management. It has developed and launched products such as the Truth Social iPad app, AI-powered search features, and premium subscription packages. The company also expanded its streaming services internationally and launched ETFs on the NYSE. Leadership includes an experienced board and an interim CEO appointed in 2026 with a background in media and advertising. The company is engaged in a major merger with TAE Technologies, a transaction that has influenced recent stock price movements.